middle.news
Acrux Accelerates Female Testosterone Development with $5M Revenue Surge and FDA Phase III Clarity
10:07am on Friday 31st of July, 2026 AEST
•
Pharmaceuticals
Read Story
Acrux Accelerates Female Testosterone Development with $5M Revenue Surge and FDA Phase III Clarity
10:07am on Friday 31st of July, 2026 AEST
Key Points
FY26 customer receipts surged 960% to $5 million
Received $1.35 million licensing milestone from Gedeon Richter
Secured $1.6 million institutional funding for Female Testosterone
FDA clarified Phase III trial pathway for Female Testosterone
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE